OIS@AAO

Ocular Therapeutix is gearing up to resubmit in the first half of 2018 its New Drug Application for its Dextenza 0.4-mg dexamethasone insert, president and…

Graybug Vision’s ongoing Phase I/II trial or GB-102 (1 mg sunitinib) injection for wet age-related macular degeneration should produce initial six-month data in Q2 2018,…

Allegro Ophthalmics is planning a 2018 Phase III trial of its lead integrin peptide therapy candidate Luminate for treatment of diabetic macular edema, president Vicken…

Ocunexus Therapeutics’ CEO Brian Levy, OD, MSc, provided an update on Ocunexus Therapeutics’ two lead candidates during the Company Showcase 3 session at OIS@AAO 2017.…

During the Company Showcase 3 session at OIS@AAO 2017 KalVista Pharmaceuticals CEO Andrew Crockett provided an update on the company’s collaboration with Merck for KVD001,…

In developing the small-molecule agent AKB-9778 to target the Tie2/VE-PTP pathway, Aerpio president and CEO Joseph Gardner, PhD, said the first-in-class agent that inhibits phosophatase…

ONL Therapeutics is using the $5 million in Series A funding it obtained in May 2017 to complete and file the investigational new drug application…

Aura Biosciences is preparing to conduct a Phase IIa trial of its light-activated AU-011 therapy for treatment of ocular melanoma, CEO Elisabet de los Pinos,…

Presenting results from the initial Phase I/II mitochondrial gene therapy for ND4 Leber’s hereditary optic nerve (LHON), GenSight’s Barrett Katz, MD, chief medical officer, stressed…

The TrueVision “story” is one of digital surgery, which allows for overlays, incorporating robotics, and incorporation of preoperative diagnostics. It’s a “virtual surgical cockpit that…

The minimally invasive glaucoma surgery (MIGS) market is expected to grow from about $164 million in 2017 to $521 million by 2022, Ivantis CEO and…

This privately held company has a “pipeline of products” to treat glaucoma, concentrating on the MINIject, a “next-generation” minimally invasive glaucoma surgery (MIGS) device. The…